Important poster: ALPHA3, the first clinical trial enrolling patients with LBCL who have complete response by PET/CT after 1L therapy but have +ctDNA. Trial in Progress poster tonight at #ASH24 #lymsm

Come join us to learn about moving CAR T-cell therapy forward in patients with lymphoma. Ongoing now at the convention center at #ASH24 @ash-hematology.bsky.social #lymsm #MedSky #OncSky

Important paper: Comparing axi-cel and liso-cel in patients receiving 3L+ therapy for relapsed large b-cell lymphoma. Outcomes similar to trials, but liso-cel takes longer and when matched, axi-cel improved PFS. @oncoalert.bsky.social
#lymsm #medsky #oncsky

Advocacy is another way we serve our patients. Rounding on the inpatient service this week, IV fluid shortages are a reminder that there is more work to do. Join us at the Advocacy Summit April 6-8, 2025. #ASCOAdvocacy #MedSky

Hey ASCO advocates, assemble! It’s time to sign up, block your calendar, and get ready to advocate for your patients. Link ⬇️ 4/6-8/2025 - Bonus: let’s follow each other. Tag your #ASCOAdvocacy friends in response below:

I’m sharing a post from X for those that aren’t on both:
The ASCO election is open and I’m honored to be on the ballot for the Board of Directors. Learn about all the amazing candidates and vote🗳️⬇️
ASCO.org/election